Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Margin % Related Terms
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Margin % Chart
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Margin % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a EBITDA Margin % of 36.16% as of Dec. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC and its competitors.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA Margin % too high?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current EBITDA Margin % is 36.16%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's value of 36.16% is 254.2% above this industry median. Overall, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA Margin % compare to FICO and SPSC?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA Margin % of 36.16% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's value of 36.16% is 254.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current EBITDA Margin % of 36.16% is 254.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current EBITDA Margin % is 36.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC stock overvalued right now?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a current EBITDA Margin % of 36.16%. The current EBITDA Margin % is 36.16% and 254.2% above the Healthcare Providers & Services industry median of 10.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA), the current EBITDA Margin % is 36.16% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Business Description
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC, through its subsidiary, is engaged in offering personal storage of cord blood stem cells in Russia and Eastern Europe. The services provided by the company include Cord Blood Cell Preservation, Program for the treatment of Cerebral Palsy, Cord Blood DNA isolation, and Umbilical Cord tissue, among others.
17GF Score
Get the complete analysis for MIC:GEMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:GEMA has been successfully added to your 
